Security key
702712100
Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG)
CUSIP: 702712100
Q2 2022 13F Holders as of 30 Jun 2022
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 42,200,841
- Total 13F value
- $99,586,412
- Share change
- -591,864
- SEC-reported price per share
- $2.36
- Number of holders
- 77
- Value change
- -$2,254,627
- Number of buys
- 34
- Number of sells
- 65
- Shares outstanding
- 3,208,376
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2022
Institutions
77
Top holders
10
PASG full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Passage BIO, Inc. SEC filings
Passage BIO, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 702712100
Recent filing periods:
Ownership snapshot
Top reported holders of PASG - Passage BIO, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2022
13F
Lead comparable stake: 229%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 229%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
229%
Frazier Life Sciences Management,...
156%
Versant Venture Management, LLC
155%
Deep Track Capital, LP
105%
BlackRock Finance, Inc.
103%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
229%
|
$22,729,000
7,331,999 shares
|
— | 31 Mar 2022 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
156%
|
$15,529,000
5,009,219 shares
|
— | 31 Mar 2022 |
| Versant Venture Management, LLC |
13F
Company
|
155%
|
$15,375,000
4,959,769 shares
|
— | 31 Mar 2022 |
| Deep Track Capital, LP |
13F
Company
|
105%
|
$10,463,000
3,375,000 shares
|
— | 31 Mar 2022 |
| BlackRock Finance, Inc. |
13F
Company
|
103%
|
$10,208,000
3,292,792 shares
|
— | 31 Mar 2022 |
| New Leaf Venture Partners, L.L.C. |
13F
Company
|
78%
|
$7,744,000
2,497,922 shares
|
— | 31 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
77
Shares
42,200,841
Rows available
77
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
99
Q2 2022 holders
77
Holder diff
-22
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 value | Q2 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend